이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

RegenETP 관리

관리 기준 확인 4/4

RegenETP's CEO는 Richard Hague, Apr2020 에 임명되었습니다 의 임기는 3.42 년입니다. 총 연간 보상은 $ 479.81K, 93.5% 로 구성됩니다. 93.5% 급여 및 6.5% 보너스(회사 주식 및 옵션 포함). 는 € 2.70K 가치에 해당하는 회사 주식의 0.62% 직접 소유합니다. 2.70K. 경영진과 이사회의 평균 재임 기간은 각각 4.3 년과 6.3 년입니다.

주요 정보

Richard Hague

최고 경영자

US$479.8k

총 보상

CEO 급여 비율	93.5%
CEO 임기	3.4yrs
CEO 소유권	0.6%
경영진 평균 재임 기간	4.3yrs
이사회 평균 재임 기간	6.3yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Richard Hague 의 보수는 RegenETP 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2023	n/a	n/a	-US$8m
Dec 31 2022	US$480k	US$449k	-US$8m
Sep 30 2022	n/a	n/a	-US$16m
Jun 30 2022	n/a	n/a	-US$13m
Mar 31 2022	n/a	n/a	-US$17m
Dec 31 2021	US$1m	US$359k	-US$30m
Sep 30 2021	n/a	n/a	-US$32m
Jun 30 2021	n/a	n/a	-US$38m
Mar 31 2021	n/a	n/a	-US$47m
Dec 31 2020	US$996k	US$358k	-US$43m
Sep 30 2020	n/a	n/a	-US$54m
Jun 30 2020	n/a	n/a	-US$70m
Mar 31 2020	n/a	n/a	-US$80m
Dec 31 2019	US$2m	US$273k	-US$92m

보상 대 시장: Richard 의 총 보상 ($USD 479.81K )은 German 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 434.78K ).

보상과 수익: Richard 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Richard Hague (63 yo)

3.4yrs

테뉴어

US$479,808

보상

Mr. Richard Hague is Director of Remedium Bio, Inc since 2022. He serves as President at PolarityTE, Inc. since August 2019 and its Chief Executive Officer since August 2021 and also served as its Chief Op...

리더십 팀

이름	위치	테뉴어	보상	소유권
Richard Hague	President	3.4yrs	US$479.81k	0.62% $ 2.7k
Nikolai Sopko	Chief Scientific Officer and VP of R&D	5.2yrs	데이터 없음	데이터 없음
Rich Haerle	Vice President of Investor Relations & Strategy	5.3yrs	데이터 없음	데이터 없음
Mark Lehman	Chief Legal Officer	no data	데이터 없음	데이터 없음
Angela Ziegler	Vice President of Marketing & Public Relations	no data	데이터 없음	데이터 없음
Alain Adam	Vice President of Sales	5.2yrs	데이터 없음	데이터 없음
Jon Anthony Burrows	Senior VP of Corporate Development & President of Contract Services	no data	데이터 없음	데이터 없음
Ryan Mathis	Chief Medical Officer	2yrs	데이터 없음	데이터 없음
Kolby Day	Senior Vice President of Manufacturing Operations	less than a year	데이터 없음	데이터 없음

4.3yrs

평균 재임 기간

경험이 풍부한 관리: NJT 의 관리팀은 경험 ( 4.3 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Richard Hague	President	less than a year	US$479.81k	0.62% $ 2.7k
Michael Callahan	Member of Clinical Advisory board	no data	데이터 없음	데이터 없음
Stephen Milner	Member of Clinical Advisory Board	6.8yrs	데이터 없음	데이터 없음
Michael Grant	Member of Clinical Advisory Board	6.8yrs	데이터 없음	데이터 없음
Anand Kumar	Member of Clinical Advisory Board	6.8yrs	데이터 없음	데이터 없음
Anthony Tufaro	Member of Clinical Advisory Board	no data	데이터 없음	데이터 없음
Trinity Bivalacqua	Member of Clinical Advisory Board	no data	데이터 없음	데이터 없음
Shannath Merbs	Member of Clinical Advisory Board	no data	데이터 없음	데이터 없음
Ryan Katz	Member of Clinical Advisory Board	no data	데이터 없음	데이터 없음
Martin Robson	Member of Clinical Advisory Board	6.3yrs	데이터 없음	데이터 없음
William Hickerson	Member of Clinical Advisory Board	6.3yrs	데이터 없음	데이터 없음
Jeffrey Shupp	Member of Clinical Advisory Board	6.3yrs	데이터 없음	데이터 없음

6.3yrs

평균 재임 기간

경험이 풍부한 이사회: NJT 의 이사회는 경험(평균 재직 기간 6.3 년)으로 간주됩니다.

RegenETP 관리

관리 기준 확인 4/4

주요 정보

최근 관리 업데이트

PolarityTE, Inc. Announces Resignation of Jacob Patterson as Chief Financial Officer

Polarityte, Inc. Appoints Jeff Dyer as A Member of the Board of Directors

Insufficient new directors

PolarityTE, Inc. Announces Resignation of Jeff Dyer from its Board of Directors

Independent Chairman of the Board recently bought €212k worth of stock

Recent updates

RegenETP, Inc. announced that it expects to receive $22.5 million in funding from Avenue Capital Group, LLC

PolarityTE Screens First Subject in Phase III Pivotal Study Evaluating Investigational New Drug SkinTE® in Diabetic Foot Ulcers

PolarityTE, Inc. Announces Resignation of Jacob Patterson as Chief Financial Officer

PolarityTE, Inc. announced delayed 10-Q filing

PolarityTE, Inc. Files Form 15

Nasdaq to Delist the Common Stock of PolarityTE

PolarityTE, Inc.(OTCPK:PTEI.Q) dropped from NASDAQ Composite Index

PolarityTE's Common Stock To Be Delisted From Nasdaq

First quarter 2023 earnings released: US$0.58 loss per share (vs US$1.12 loss in 1Q 2022)

Forecast to breakeven in 2025

Polarityte, Inc. Appoints Jeff Dyer as A Member of the Board of Directors

Insufficient new directors

Forecast to breakeven in 2025

Third quarter 2022 earnings released: US$0.47 loss per share (vs US$0.31 loss in 3Q 2021)

Third quarter 2022 earnings released: US$0.47 loss per share (vs US$0.31 loss in 3Q 2021)

Michael Brauser submitted a non-binding offer to acquire the remaining stake in PolarityTE, Inc. (NasdaqCM:PTE).

PolarityTE, Inc. Receives Deficiency Letter the Listing Qualifications Department of Nasdaq

PolarityTE, Inc. Announces Resignation of Jeff Dyer from its Board of Directors

Second quarter 2022 earnings released: US$0.013 loss per share (vs US$0.99 loss in 2Q 2021)

PolarityTE, Inc. to Report Q2, 2022 Results on Aug 11, 2022

First quarter 2022 earnings released: US$0.045 loss per share (vs US$0.23 loss in 1Q 2021)

PolarityTE, Inc. Announces FDA Regenerative Medicine Advanced Therapy Designation Granted to SkinTE(R)

PolarityTE, Inc. to Report Q1, 2022 Results on May 16, 2022

Full year 2021 earnings released: US$0.38 loss per share (vs US$1.11 loss in FY 2020)

PolarityTE, Inc. Announces Results from Multi-Center Randomized Controlled Trial Evaluating Treatment of Venous Leg Ulcers with Its Investigational Product SkinTE plus standard of care vs SOC alone

PolarityTE, Inc. Announces Allowance of Fourth U.S. Patent

PolarityTE, Inc Announces U.S. FDA Approval of IND for Pivotal Phase 3 Study of SkinTE® to Support Chronic Cutaneous Ulcer Indication

PolarityTE, Inc. Announces Submission of Complete Response to Fda's Clinical Hold Correspondence for Skinte® Investigational New Drug Application

Third quarter 2021 earnings released: US$0.013 loss per share (vs US$0.18 loss in 3Q 2020)

Gainey Mckenna & Egleston Announces A Class Action Lawsuit Filed Against PolarityTE, Inc

Independent Director Minnie Baylor-Henry has left the company

PolarityTE Provides Update on U.S. FDA Investigational New Drug Application for SkinTE®

PolarityTE Receives A Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Second quarter 2021 earnings released: US$0.04 loss per share (vs US$0.33 loss in 2Q 2020)

Independent Chairman of the Board recently bought €212k worth of stock

First quarter 2021 earnings released: US$0.23 loss per share (vs US$0.40 loss in 1Q 2020)

PolarityTE, Inc. Updates on SkinTE Biologic License Application

PolarityTE Announces Diabetic Foot Ulcer Trial Met Primary and Secondary Endpoint

PolarityTE, Inc. to Report Fiscal Year 2020 Results on Mar 30, 2021

PolarityTE, Inc. Announces Submission of an Investigational New Drug Application

New 90-day high: €1.23

PolarityTE Announces Completion of Target Enrollment in Diabetic Foot Ulcer Trial

PolarityTE, Inc. has completed a Follow-on Equity Offering in the amount of $10.000001 million.

New 90-day high: €0.98

New 90-day low: €0.53

Polarityte Announces Dismissal of Securities Class Action Complaint with Prejudice

New 90-day low: €0.57

Third quarter 2020 earnings released: US$0.18 loss per share

Revenue beats expectations

PolarityTE Announces Successful Completion of Initial Pre-IND Interaction with U.S. Food and Drug Administration for SkinTE®

PolarityTE, Inc. to Report Q3, 2020 Results on Nov 09, 2020

New 90-day low: €0.82

PolarityTE Receives NIH Grant for a Point-of-Care Device to Treat Chronic Wounds

New 90-day low: €0.85

PolarityTE, Inc. Announces SkinTE™ Health Economics — DFU Interim Analysis Data Demonstrates Potential for Cost Savings and Improved Wound Closure

New 90-day low - €0.94

First half earnings released

New 90-day high - €1.47

PolarityTE, Inc.(NasdaqCM:PTE) dropped from Russell Small Cap Completeness Index

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

이사회 구성원

평균 재임 기간